Base de dados : MEDLINE
Pesquisa : C19.642.355.480 [Categoria DeCS]
Referências encontradas : 5027 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 503 ir para página                         

  1 / 5027 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465577
[Au] Autor:Peng T; Hu Z; Yang X; Gao Y; Ma C
[Ad] Endereço:Department of Nephrology, Shandong University Qilu Hospital, Jinan City, China.
[Ti] Título:Nitrite-induced acute kidney injury with secondary hyperparathyroidism: Case report and literature review.
[So] Source:Medicine (Baltimore);97(8):e9889, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Acute kidney injury (AKI) with hyperparathyroidism caused by nitrite was rare, and renal function and parathyroid hormone (PTH) decreased to normal range after therapy. PATIENT CONCERNS: Acute kidney injury was diagnosed in a 40-year-old male with hyperparathyroidism and cyanosis of his hands and both forearms. DIAGNOSES: The patient ate some recently pickled vegetables, and he experienced nausea, vomiting and diarrhoea without oliguria or anuria; Additionally, his hands and both forearms had a typical blue ash appearance. After admission, the laboratory findings indicated theincreasing serum creatinine (Scr) and parathyroid hormone (PTH). He was diagnosed as acute kidney injury with hyperparathyroidism caused by nitrite. INTERVENTIONS: The patient stopped eating the pickled vegetables and was given rehydration, added calories and other supportive therapy without any glucocorticoids. OUTCOMES: According to his clinical manifestations, laboratory findings and imaging results, the patient was diagnosed with acute kidney injury with secondary hyperparathyroidism. He was given symptomatic supportive care therapy. After one week, the serum creatinine, parathyroid hormone (PTH), hypercalcemia, hyperphosphatemia, proteinuria, and urine red blood cell values decreased to normal range. LESSONS: Nitrite-induced acute kidney injury with secondary hyperparathyroidism was relatively rare. After therapy, the function of the kidney and parathyroid returned to normal. This case suggests that detailed collection of medical history, physical examination and correct symptomatic treatment is very important.
[Mh] Termos MeSH primário: Lesão Renal Aguda/induzido quimicamente
Hiperparatireoidismo Secundário/induzido quimicamente
Nitritos/envenenamento
[Mh] Termos MeSH secundário: Lesão Renal Aguda/terapia
Adulto
Cianose/induzido quimicamente
Diarreia/induzido quimicamente
Hidratação
Conservação de Alimentos
Seres Humanos
Hiperparatireoidismo Secundário/terapia
Masculino
Náusea/induzido quimicamente
Apoio Nutricional
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Nitrites)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009889


  2 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309106
[Au] Autor:Poskurica M; Poskurica M; Petrovic D
[Ti] Título:Secondary hyperparathyroidism in chronic renal disease - etiopathogenesis, diagnosis and treatment.
[So] Source:Vojnosanit Pregl;73(4):376-81, 2016 Apr.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Mh] Termos MeSH primário: Hiperparatireoidismo Secundário/etiologia
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Seres Humanos
Hiperparatireoidismo Secundário/diagnóstico
Hiperparatireoidismo Secundário/tratamento farmacológico
Hiperparatireoidismo Secundário/fisiopatologia
Hormônio Paratireóideo/biossíntese
Hormônio Paratireóideo/secreção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Parathyroid Hormone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.2298/VSP141218024P


  3 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29238762
[Au] Autor:Ureña Torres PA; Bover J; Cohen-Solal M
[Ad] Endereço:Ramsay-Générale de Santé, Clinique du Landy, Department of Nephrology and Dialysis and Department of Renal Physiology, Necker Hospital, University of Paris Descartes, Paris, France. pablo.urena@wanadoo.fr.
[Ti] Título:Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
[So] Source:Drugs Today (Barc);53(9):489-500, 2017 Sep.
[Is] ISSN:1699-3993
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:Chronic kidney disease is associated with mineral and bone disorders that are now considered as a syndrome. One of the major complications of this syndrome is secondary hyperparathyroidism (SHPT). SHPT increases bone turnover and the risk of fracture. SHPT is also associated with cardiovascular calcification and high mortality risk. The classical medical therapies of SHPT lack long-term efficacy and have undesirable effects on serum calcium and phosphate levels. Surgical parathyroidectomy is a radical therapeutic solution potentially exposing patients to a permanent state of hypoparathyroidism among other complications. Oral cinacalcet revolutionized the treatment of SHPT because of its great efficacy; however, more than one-third of patients do not respond appropriately to cinacalcet, mostly because of intolerance and lack of compliance. Intravenous etelcalcetide improves medical adherence and reduces pill burden. It is 10-15% superior than cinacalcet in controlling parathyroid hormone, but also leads to more frequent episodes of hypocalcemia.
[Mh] Termos MeSH primário: Hiperparatireoidismo Secundário/tratamento farmacológico
Peptídeos/administração & dosagem
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Animais
Cloridrato de Cinacalcete/efeitos adversos
Cloridrato de Cinacalcete/uso terapêutico
Seres Humanos
Hiperparatireoidismo Secundário/etiologia
Adesão à Medicação
Hormônio Paratireóideo/metabolismo
Peptídeos/efeitos adversos
Peptídeos/farmacologia
Diálise Renal/métodos
Insuficiência Renal Crônica/terapia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AMG-416); 0 (Parathyroid Hormone); 0 (Peptides); 1K860WSG25 (Cinacalcet Hydrochloride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.1358/dot.2017.53.9.2711938


  4 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245308
[Au] Autor:Li JG; Xiao ZS; Hu XJ; Li Y; Zhang X; Zhang SZ; Shan AQ
[Ad] Endereço:aDepartment of Thyroid Breast SurgerybDepartment of Nephrology, Yinzhou Hospital of Ningbo University Medical College, Ningbo, China.
[Ti] Título:Total parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients.
[So] Source:Medicine (Baltimore);96(49):e9050, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Our study aims to explore the effect of total parathyroidectomy (PTX) with forearm autotransplantation (FAT) on the quality of life and recurrence of secondary hyperparathyroidism (SHPT) in chronic kidney disease patients. METHODS: A total of 104 chronic kidney disease patients with SHPT were enrolled and divided into the PTX (n = 62) and PTX + FAT (n = 42) groups. The operation efficacy was evaluated by analyzing preoperative and postoperative values, including levels of intact parathyroid hormone (iPTH), serum phosphorus, serum calcium, alkaline phosphatase (ALP), calcium-phosphorus product, signs and symptoms, and MOS 36-item short-form health survey (SF-36) scores. Moreover, complications and recurrences were followed up for 12 months after the operation. Binary logistic regression was to present the risk factors for the recurrence of chronic kidney disease patients with SHPT. RESULTS: Compared with the preoperative values, the PTX and PTX + FAT groups showed decrease postoperative levels of iPTH, serum phosphorus, serum calcium, calcium-phosphorus product, bone pain, and skin pruritus at all time periods. The PTX and PTX + FAT groups demonstrated decreased ALP, fracture or deformity, and coronary artery calcification at 1 month, decreased short stature at 3 months after the operation but increased SF-36 score after operation. Compared with the PTX group, the level of iPTH decreased and the levels of serum calcium, calcium-phosphorus product increased at 3, 6, and 12 months after the operation in the PTX + FAT group. The levels of ALP, fracture or deformity, short stature, and SF-36 decreased separately at 1 week and 6 and 12 months after the operation, along with the decrease of coronary artery calcification and the recurrence rate, respectively, at 6 and 12 months after the operation in the PTX + FAT group when compared with those in the PTX group. Logistic regression analysis evidenced that the preoperative iPTH level, SF-36 score, and operation type were the risk factors for the recurrence of chronic kidney disease with SHPT. CONCLUSION: Total PTX combined with FAT is more effective in improving the quality of life and reducing the recurrence of chronic kidney disease with SHPT than PTX alone.
[Mh] Termos MeSH primário: Antebraço/cirurgia
Hiperparatireoidismo Secundário/cirurgia
Glândulas Paratireoides/transplante
Paratireoidectomia/métodos
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Fosfatase Alcalina/sangue
Cálcio/sangue
Terapia Combinada
Feminino
Seguimentos
Seres Humanos
Hiperparatireoidismo Secundário/sangue
Hiperparatireoidismo Secundário/etiologia
Masculino
Meia-Idade
Hormônio Paratireóideo/sangue
Fósforo/sangue
Qualidade de Vida
Recidiva
Transplante Autólogo/métodos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Parathyroid Hormone); 27YLU75U4W (Phosphorus); EC 3.1.3.1 (Alkaline Phosphatase); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009050


  5 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29192005
[Au] Autor:Srivastava T; Jafri S; Truog WE; Sebestyen VanSickle J; Manimtim WM; Alon US
[Ad] Endereço:Sections of Nephrology, Bone and Mineral Disorder Clinic, and.
[Ti] Título:Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet.
[So] Source:Pediatrics;140(6), 2017 Dec.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Secondary hyperparathyroidism (SHPT) is a rare complication of furosemide therapy that can occur in patients treated with the loop diuretic for a long period of time. We report a 6-month-old 28-weeks premature infant treated chronically with furosemide for his bronchopulmonary dysplasia, who developed hypocalcemia and severe SHPT, adversely affecting his bones. Discontinuation of the loop diuretic and the addition of supplemental calcium and calcitriol only partially reversed the SHPT, bringing serum parathyroid hormone level down from 553 to 238 pg/mL. After introduction of the calcimimetic Cinacalcet, we observed a sustained normalization of parathyroid hormone concentration at 27 to 63 pg/mL and, with that correction, of all biochemical abnormalities and healing of the bone disease. No adverse effects were noted. We conclude that in cases of SHPT due to furosemide in which traditional treatment fails, there may be room to consider the addition of a calcimimetic agent.
[Mh] Termos MeSH primário: Calcimiméticos/uso terapêutico
Cálcio/sangue
Cloridrato de Cinacalcete/uso terapêutico
Furosemida/efeitos adversos
Hiperparatireoidismo Secundário/induzido quimicamente
[Mh] Termos MeSH secundário: Seres Humanos
Lactente
Imagem por Ressonância Magnética
Masculino
Hormônio Paratireóideo/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcimimetic Agents); 0 (Parathyroid Hormone); 1K860WSG25 (Cinacalcet Hydrochloride); 7LXU5N7ZO5 (Furosemide); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  6 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29078836
[Au] Autor:Morsy MS; Dishmon DA; Garg N; Weber KT
[Ad] Endereço:Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, Tennessee.
[Ti] Título:Secondary Hyperparathyroidism in Heart Failure.
[So] Source:Am J Med Sci;354(4):335-338, 2017 Oct.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Secondary hyperparathyroidism (SHPT) is a well-known pathophysiologic feature of chronic renal failure. In recent years, SHPT has become recognized as a complication of the aldosteronism associated with congestive heart failure and where excretory Ca and Mg wasting results in plasma-ionized hypocalcemia and hypomagnesemia. Elevations in plasma parathyroid hormone have adverse systemic consequences, including intracellular Ca overloading of myocytes and vascular smooth muscle with the induction of oxidative stress. Herein, we briefly review the presence and adverse outcomes of SHPT in persons with heart failure.
[Mh] Termos MeSH primário: Cálcio/sangue
Insuficiência Cardíaca/sangue
Hiperparatireoidismo Secundário/sangue
Magnésio/sangue
Hormônio Paratireóideo/sangue
Insuficiência Renal Crônica/sangue
[Mh] Termos MeSH secundário: Animais
Insuficiência Cardíaca/patologia
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Hiperparatireoidismo Secundário/patologia
Hiperparatireoidismo Secundário/fisiopatologia
Músculo Liso Vascular/metabolismo
Músculo Liso Vascular/patologia
Músculo Liso Vascular/fisiopatologia
Miócitos Cardíacos/metabolismo
Miócitos Cardíacos/patologia
Insuficiência Renal Crônica/patologia
Insuficiência Renal Crônica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Parathyroid Hormone); I38ZP9992A (Magnesium); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171029
[St] Status:MEDLINE


  7 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29040300
[Au] Autor:Jäger MD; Serttas M; Beneke J; Müller JA; Schrem H; Kaltenborn A; Ramackers W; Ringe BP; Gwiasda J; Tränkenschuh W; Klempnauer J; Scheumann GFW
[Ad] Endereço:Klinik für Allgemein-, Viszeral- und Minimal-Invasive Chirurgie, Städtisches Klinikum Wolfenbüttel gGmbH, Wolfenbüttel, Germany.
[Ti] Título:Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients.
[So] Source:PLoS One;12(10):e0186093, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Nodular hyperplasia of parathyroid glands (PG) is the most probable cause of medical treatment failure in secondary hyperparathyroidism (sHPT). This prospective cohort study is located at the interface of medical and surgical consideration of sHPT treatment options and identifies risk-factors for nodular hyperplasia of PG. MATERIAL AND METHODS: One-hundred-eight resected PG of 27 patients with a broad spectrum of sHPT severity were classified according to the degree of hyperplasia by histopathology. Twenty routinely gathered parameters from medical history, ultrasound findings of PG and laboratory results were analyzed for their influence on nodular hyperplasia of PG by risk-adjusted multivariable binary regression. A prognostic model for non-invasive assessment of PG was developed and used to weight the individual impact of identified risk-factors on the probability of nodular hyperplasia of single PG. RESULTS: Independent risk-factors for nodular hyperplasia of single PG were duration of dialysis in years, PG volume in mm3 determined by ultrasound and serum level of parathyroid hormone in pg/mL. Multivariable analyses computed a model with an Area Under the Receiver Operative Curve of 0.857 (95%-CI:0.773-0.941) when predicting nodular hyperplasia of PG. Theoretical assessment of risk-factor interaction revealed that the duration of dialysis had the strongest influence on the probability of nodular hyperplasia of single PG. CONCLUSIONS: The three identified risk-factors (duration of dialysis, PG volume determined by ultrasound and serum level of parathyroid hormone) can be easily gathered in daily routine and could be used to non-invasively assess the probability of nodular hyperplasia of PG. This assessment would benefit from periodically collected data sets of PG changes during the course of sHPT, so that the choice of medical or surgical sHPT treatment could be adjusted more to the naturally changing type of histological PG lesion on an individually adopted basis in the future.
[Mh] Termos MeSH primário: Hiperparatireoidismo Secundário/patologia
Glândulas Paratireoides/patologia
Hormônio Paratireóideo/sangue
Paratireoidectomia
Diálise Renal
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores/análise
Feminino
Seres Humanos
Hiperparatireoidismo Secundário/sangue
Hiperparatireoidismo Secundário/diagnóstico por imagem
Hiperparatireoidismo Secundário/cirurgia
Hiperplasia
Meia-Idade
Tamanho do Órgão
Glândulas Paratireoides/diagnóstico por imagem
Glândulas Paratireoides/cirurgia
Prognóstico
Estudos Prospectivos
Curva ROC
Fatores de Risco
Fatores de Tempo
Ultrassonografia Doppler
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Parathyroid Hormone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171018
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186093


  8 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28846459
[Au] Autor:Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
[Ad] Endereço:a Department of Health Sciences, Renal Division , University of Milan , Milan , Italy.
[Ti] Título:Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
[So] Source:Expert Rev Clin Pharmacol;10(10):1073-1084, 2017 Oct.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Deranged vitamin D metabolism represents an active trigger of secondary hyperparathyroidism (SHPT) in CKD. Correction of 25(OH)D deficiency by nutritional Vitamin D administration is suggested by KDIGO guidelines, to prevent and treat SHPT in CKD stage G3-G5 and G1T-G5T patients, although with a still inconsistent background. Nutritional vitamin D is available as cholecalciferol, ergocalciferol, or calcifediol. Superiority of calcifediol in increasing 25(OH)D levels has been suggested due to its better bioavailability. The safer pharmacokinetic of the recent modified-release (MR) formulation of calcifediol was effective in replenishing 25(OH)D levels with minimal impact on vitamin D catabolism and fibroblast-growth factor-23 (FGF-23) activation. Areas covered: the review discusses utility of calcifediol for treating SHPT in different CKD stages under physiology driven approach, focusing on vitamin D metabolism, guidelines suggestions and comparison between clinical effects on SHPT elicited by calcifediol, cholecalciferol and ergocalciferol. Expert commentary: although optimal targets of 25(OH)D and parathormone remain uncertain, calcifediol, especially in its newer MR formulation, may represent an intriguing option to combine an efficacious correction of 25(OH)D deficit and SHPT, with a limited impact on vitamin D catabolism and FGF-23 activation. Newer data are required to better explore the role of MR calcifediol in treating SHPT.
[Mh] Termos MeSH primário: Calcifediol/uso terapêutico
Hiperparatireoidismo Secundário/tratamento farmacológico
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Animais
Disponibilidade Biológica
Calcifediol/administração & dosagem
Calcifediol/farmacocinética
Colecalciferol/uso terapêutico
Preparações de Ação Retardada
Ergocalciferóis/uso terapêutico
Seres Humanos
Hiperparatireoidismo Secundário/etiologia
Guias de Prática Clínica como Assunto
Vitamina D/análogos & derivados
Vitamina D/sangue
Vitamina D/metabolismo
Vitaminas/administração & dosagem
Vitaminas/farmacocinética
Vitaminas/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Ergocalciferols); 0 (Vitamins); 1406-16-2 (Vitamin D); 1C6V77QF41 (Cholecalciferol); 64719-49-9 (25-hydroxyvitamin D); P6YZ13C99Q (Calcifediol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1371011


  9 / 5027 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28622150
[Au] Autor:Rosenkrans DJ; Kolarczyk LM
[Ad] Endereço:From the Department of Anesthesiology, University of North Carolina Hospitals, Chapel Hill, North Carolina.
[Ti] Título:Intraoperative Hyperkalemia and Ventricular Arrhythmia During Parathyroidectomy: A Case Report.
[So] Source:A A Case Rep;9(4):105-108, 2017 Aug 15.
[Is] ISSN:2325-7237
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We present a case of acute hyperkalemia and ventricular arrhythmia during parathyroidectomy in a patient with end-stage renal disease. This case highlights the under-recognized alterations in potassium homeostasis associated with parathyroidectomy and underscores the importance of preoperative optimization.
[Mh] Termos MeSH primário: Arritmias Cardíacas/etiologia
Hiperpotassemia/etiologia
Hiperparatireoidismo Secundário/cirurgia
Paratireoidectomia/efeitos adversos
[Mh] Termos MeSH secundário: Seres Humanos
Hiperparatireoidismo Secundário/complicações
Período Intraoperatório
Falência Renal Crônica/complicações
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170617
[St] Status:MEDLINE
[do] DOI:10.1213/XAA.0000000000000539


  10 / 5027 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28579010
[Au] Autor:Wémeau JL; Cardot-Bauters C
[Ad] Endereço:Université de Lille 2, Lille, France. Electronic address: jl-wemeau@hotmail.fr.
[Ti] Título:[Maxillary, buccal and dental expressions of hyperparathyroidisms].
[Ti] Título:Manifestations maxillo-buccodentaires des hyperparathyroïdies..
[So] Source:Presse Med;46(9):845-852, 2017 Sep.
[Is] ISSN:2213-0276
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:States of chronic parathyroid hypersecretion, related to a primitive parathyroid abnormality (adenoma, hyperplasia), or to a cause of chronic calcipenia (renal failure, vitamin D deficiency…) have a major impact on bone remodeling, alveolodental structures. Thinning of the lamina dura, maxillary or mandibular brown tumors, giant cell epulis are the most emblematic signs of the primary hyperparathyroidism. Other expressions are related to genetic factors such as fibrous tumors of the jaw in conjunction with mutations in the gene coding for parafibromin.
[Mh] Termos MeSH primário: Hiperparatireoidismo Primário/diagnóstico
Hiperparatireoidismo Secundário/diagnóstico
Doenças Maxilares/diagnóstico
Doenças da Boca/diagnóstico
Odontopatias/diagnóstico
[Mh] Termos MeSH secundário: Doença Crônica
Diagnóstico Diferencial
Seres Humanos
Hiperparatireoidismo Primário/complicações
Hiperparatireoidismo Primário/etiologia
Hiperparatireoidismo Primário/terapia
Hiperparatireoidismo Secundário/complicações
Hiperparatireoidismo Secundário/etiologia
Hiperparatireoidismo Secundário/terapia
Doenças Maxilares/etiologia
Doenças da Boca/etiologia
Prognóstico
Odontopatias/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE



página 1 de 503 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde